CHMP positive opinion regarding Somatropin Biopartners
Biopartners GmbH, a wholly owned subsidiary of Bioton SA, Poland, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion regarding the approval of once-weekly Somatropin Biopartners for the treatment of growth hormone deficiency (GHD) in paediatric and adult patients.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | European Medicines Agency (EMA) | Hormones | Nutropin AQ | Pediatrics